Purpose Investments Inc. Announces Risk Rating Change
TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) today announced a change to the risk rating of one of its funds effective immediately.
The change in risk rating is the result of the implementation of the standardized risk classification methodology pursuant to National Instrument 81-102 – Investment Funds and is not the result of any change to the investment objectives, strategies or management of the fund.
| Fund | Current | New |
| Purpose Structured Equity Growth Fund | Low to Medium | Medium |
Please consult your advisor and read the simplified prospectus or fund facts of the fund before investing.
About Purpose Investments Inc.
Purpose Investments is an asset management company with approximately $20 billion in assets under management. Purpose Investments has an unrelenting focus on client-centric innovation and offers a range of managed and quantitative investment products. Purpose Investments is led by well-known entrepreneur Som Seif and is a division of Purpose Unlimited, an independent technology-driven financial services company.
For further information, please contact:
Keera Hart
[email protected]
905-580-1257
Commissions, trailing commissions, management fees, and expenses may all be associated with investment fund investments. Please read the prospectus and other disclosure documents before investing. Investment funds are not guaranteed; their values change frequently, and past performance may not be repeated. There can be no assurance that the full amount of your investment in the fund will be returned to you. If the securities are purchased or sold on a stock exchange, you may pay more or receive less than the current net asset value. Investment funds are not guaranteed; their values change frequently, and past performance may not be repeated.
Source: Purpose Investments Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- CorelDRAW 2026 Review: New Features and Workflow Updates for Designers and Print Professionals Highlighted by Expert Consumers
- Airworthy.com Releases 2026 State of General Aviation Parts Report
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share